Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (NCT02130557) | Pfizer | 2014-07-15 |
Track Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive automatically
Every clearance here is in the API, with alerts when new ones post.